- Program Overview
- Primary Management of Chronic-Phase CML
- Changing TKIs due to Intolerance: Second-line Therapy and Toxicity Management
- Changing TKIs due to CML Progression: Second-line Therapy and Future Options
- Closing Remarks and Question and Answer Session
Date / Time
The goal of this activity is to improve the competence of learners to apply the latest guidance and clinical data in the management of individuals with chronic myeloid leukemia.
This program is intended for global hematologists, medical oncologists, and other clinicians who care for patients with CML.
- Manage treatment-related toxicities, such as GI toxicities, associated with use of TKIs in patients with CML
- Increase patient involvement in the initiation of treatment, monitoring of response, managing toxicity, and adherence
- Select individualized frontline therapy for patients with chronic-phase CML, taking into consideration patient age, medical history and comorbidities, and risk score (Sokal or Euro score)
- Monitor first-line treatment responses and determine optimal timing of therapy changes
- Evaluate the available evidence, potential predictive factors, patient preferences, and expert recommendations guiding potential therapy discontinuation and treatment-free remissions
- Plan second-line, third-line, and later therapeutic strategies to manage resistance after previous TKI failure
- Describe research to increase the number of patients able to discontinue treatment through combination of TKIs with novel agents
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Designation of Credit
Physician Continuing Education
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.